Home > Neurology > EAN 2019 > Migraine > Fremanezumab results of the FOCUS study

Fremanezumab results of the FOCUS study

EAN 2019
Phase 3, FOCUS
The overall positive efficacy and safety/tolerability results of fremanezumab in the placebo-controlled FOCUS study were reported in different posters. Participants had episodic or chronic migraine and inadequate response to 2-4 classes of migraine preventive medications. A total of 838 patients were randomised to monthly fremanezumab (month 1: chronic migraine, 675 mg & episodic migraine, 225 mg; months 2 and 3: 225 mg), quarterly fremanezumab (month 1: 675 mg; months 2 and 3: placebo), or matched monthly placebo. Reductions in monthly average migraine days, clinically meaningful response rates within 4 weeks, and sustained ≥50% response rates over 3 months were significantly greater with fremanezumab vs placebo (both P<0.0001; see Table) [1]. Higher proportions of patients achieved ≥50% and ≥75% reductions in migraine days within 4 weeks and sustained ≥50% reductions through the 12-week treatment period with fremanezumab versus placebo.

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on